2023 World Conference on Lung Cancer (Posters)-EP11.03. Dose the Histological Subtype of NSCC-NOS Affect the Efficacy of 1st-Line PD-1/PD-L1 Inhibitors with or without Chemotherapy?

EP11.03. Dose the Histological Subtype of NSCC-NOS Affect the Efficacy of 1st-Line PD-1/PD-L1 Inhibitors with or without Chemotherapy? - PDF(Abstract)

Back to course

Pdf Summary

This study aimed to evaluate the efficacy of first-line PD-1/PD-L1 inhibitors with or without chemotherapy in patients with non-small cell lung cancer (NSCLC) and different histological subtypes. The study included 133 patients who were treated between January 2016 and July 2022. The histological subtypes were classified as adenocarcinoma (Ad), squamous cell carcinoma (Sq), favor adenocarcinoma (favor Ad), favor squamous cell carcinoma (favor Sq), and non-small cell carcinoma-not otherwise specified (NSCC-NOS).<br /><br />The results showed that the objective response rate (ORR) and progression-free survival (PFS) were similar between patients with Ad/favor Ad and Sq/favor Sq subtypes. However, patients with NSCC-NOS had a higher ORR compared to patients with other subtypes. Kaplan-Meier survival analysis also showed that patients with NSCC-NOS had better PFS and overall survival (OS) rates compared to patients with other subtypes.<br /><br />The findings suggest that the histological subtype of NSCLC, specifically NSCC-NOS, can influence the efficacy of first-line PD-1/PD-L1 inhibitors with or without chemotherapy. Further investigations are needed to better understand the association between histological differentiation in cancer and the effectiveness of PD-1/PD-L1 inhibitors. This study highlights the importance of considering the histological subtype in treatment decisions for NSCLC patients.

Asset Subtitle

Tatsuya Hirano

Meta Tag

Speaker Tatsuya Hirano

Topic Metastatic NSCLC: Immunotherapy - Retrospective

Keywords

PD-1/PD-L1 inhibitors

chemotherapy

NSCLC

histological subtypes

adenocarcinoma

squamous cell carcinoma

non-small cell carcinoma-not otherwise specified

objective response rate

progression-free survival

treatment decisions